Toll Biotech Secures ￥10 Million in Angel Round of Financing

(VCBeat) Mar. 10, 2021 -- Beijing-based Tuoling Biotechnology Co., Ltd. ("Toll Biotech") announced it has closed tens of millions of yuan in the angel round of financing, led by Lotus Lake Ventures, with participation from Beijing Life Science Park Venture Capital. The investment will enable Toll Biotech to accelerate the R&D of new drugs for autoimmune diseases. The company has completed related work in the R&D project of drug candidate screening and medicinal research.

Recently, Toll Biotech also announced that it has cooperated with Medicilon and has officially started the pre-clinical study of its project for the treatment of rheumatoid arthritis in the R&D pipeline to accumulate data for its subsequent application of clinical certification.

Founded in April 2020, The company has a number of patents in small molecules that can regulate the innate immune system, covering major drug R&D countries and regions in the world.

 Professor Yin Hang, the founder of Toll Biotech, has done sufficient research in the immune regulation mechanism in autoimmune diseases for more than ten years. He has developed multiple series of small molecular drug candidates based on new targets and different mechanisms for autoimmune diseases and carried out medicinal researches on these candidates. Multiple pipelines have been rapidly advanced in R&D for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and scleroderma.

There is still a huge market gap in drugs for autoimmune diseases worldwide. The drugs that have been marketed generally have problems such as low response rate of patients, excessively expensive prices, and strong side effects. Toll Biotech's R&D projects in progress focus on new targets and mechanisms for autoimmune diseases, which is are about to play an important role in the existing market. Those new drugs are expected to make up for the defects of existing drugs, and accelerate the rapid growth of the market, expand the scale of the market, and provide accessible solutions for patients.

Founded in 2001, Lotus Lake Ventures is an investment firm committed to investing in science and technology enterprises with core competitiveness in the early and growth stage in the fields of information technology, life science, and clean technology, etc.

Under the leadership of Zhongguancun Development Group and Zhongguancun Capital, Beijing Life Science Park Venture Capital is a professional fund focusing on scientific and technological innovation investment and financing services. The Fund invests in high-tech and high-growth enterprises in the early and growth stages, covering the fields of biopharmaceuticals, high-end medical devices, life information technology, biosynthesis technology, high-end medical services and so on.